JCAR017
Drug
Celgene Corporation
Total Payments
$28.4M
Transactions
509
Doctors
118
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $21.1M | 402 | 106 |
| 2018 | $7.3M | 107 | 32 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27.8M | 147 | 98.2% |
| Consulting Fee | $435,707 | 110 | 1.5% |
| Travel and Lodging | $44,520 | 105 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,159 | 11 | 0.1% |
| Food and Beverage | $8,341 | 136 | 0.0% |
Payments by Type
Research
$27.8M
147 transactions
General
$504,726
362 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM) (JCAR017-BCM-003) | Celgene Corporation | $8.2M | 0 |
| JCAR017-BCM-003 - A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFOR | Celgene Corporation | $5.1M | 0 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (17001) | Celgene Corporation | $3.8M | 0 |
| Expanded Access Protocol (EAP) of patients receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release (JCAR017-NHL-001) | Celgene Corporation | $3.3M | 0 |
| A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas3 (HuJCAR017-BCM) | Celgene Corporation | $1.9M | 0 |
| A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas3 (JCAR-017-BCM) | Celgene Corporation | $1.8M | 0 |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/?Refractory B-cell Malignancies (PLATFORM) (JCAR017-BCM-002) | Celgene Corporation | $1.4M | 0 |
| JCAR17 Non-specific-1525 - 5-NA-NA-Milestone 3: Sequencing: Research-grade double stranded primer walking with | Celgene Corporation | $750,000 | 0 |
| JCAR017-TRANSCEND-NHL-001 - A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (N | Celgene Corporation | $654,006 | 0 |
| JCAR017-BCM-002 - A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/?Refractory B-cell Malignancies (PLATFORM) | Celgene Corporation | $301,241 | 0 |
| JCAR-017-BCM - A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas3 | Celgene Corporation | $212,552 | 0 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (JCAR017-NHL-001-1525) | Celgene Corporation | $114,408 | 1 |
| Non?treatment Protocol to Collect Peripheral Blood Mononuclear (PBMCs) from Patients with Cance (CAR017-Pt Derived AP) | Celgene Corporation | $112,084 | 0 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (17007) | Celgene Corporation | $67,472 | 3 |
| TRANSCEND-CLL-004 | Celgene Corporation | $44,053 | 0 |
| A GLOBAL, NON-INTERVENTIONAL, RETROSPECTIVE, MULTI-CENTER STUDY TO GENERATE REAL-WORLD EVIDENCE OF TREATMENT OUTCOMES IN SUBJECTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (NDS-NHL-001) | Celgene Corporation | $36,556 | 0 |
| A study related to non-Hodgkin lymphoma, compares the efficacy of obinutizumab in combination with chemotherapy versus rituximab- based treatments for untreated advanced cases (CL-NHL-13648) | Celgene Corporation | $30,600 | 20 |
| JCAR017-Pt Derived AP-1525 - JCAR017-Pt Derived AP-1525 | Celgene Corporation | $16,500 | 0 |
| Patient-Derived Blood and Tissue Procurement Protocol (JCAR017-Non-Specific-1170) | Celgene Corporation | $12,090 | 0 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001), A Phase 2 study of JCAR017 as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL & OUTREACH 3L+ LBCL 017007 (017001, 017006, 017007) | Celgene Corporation | $10,604 | 10 |
Top Doctors Receiving Payments for JCAR017 — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Roger Muller | — | Tigard, OR | $3,645 | 3 |
| , M.D | Nephrology | Springfield, MA | $3,600 | 1 |
| Michael Bishop | Hematology & Oncology | Burr Ridge, IL | $3,475 | 6 |
| , MD PHD | Hematology & Oncology | Seattle, WA | $3,390 | 2 |
| Alison Sehgal | Hematology & Oncology | Pittsburgh, PA | $3,272 | 4 |
| Syed Abutalib | Medical Oncology | Zion, IL | $3,188 | 1 |
| , MD | Internal Medicine | Milwaukee, WI | $3,164 | 4 |
| , M.D | Medical Oncology | Houston, TX | $3,081 | 3 |
| , MD | Medical Oncology | New York, NY | $3,055 | 2 |
| , MD | Hematology | New York, NY | $3,031 | 2 |
| , MD | Independent Medical Examiner | Detroit, MI | $2,825 | 1 |
| , M.D | Hematology & Oncology | New York, NY | $2,825 | 1 |
| , M.D., PH.D | Hematology & Oncology | Cleveland, OH | $2,825 | 1 |
| , MD | Hospitalist | Columbus, OH | $2,781 | 4 |
| , MD | Medical Oncology | Philadelphia, PA | $2,555 | 2 |
| , MD | Medical Oncology | Aurora, CO | $2,500 | 2 |
| , MD | Hematology & Oncology | Buffalo, NY | $2,400 | 1 |
| , MD | Hematology & Oncology | Lexington, KY | $2,337 | 3 |
| , MD | Medical Oncology | Palo Alto, CA | $2,305 | 2 |
| , MD | Hematology & Oncology | Portland, OR | $2,288 | 2 |
| , MD | Orthopaedic Surgery | Lincolnton, NC | $2,220 | 1 |
| , M.D | Hematology & Oncology | Houston, TX | $2,149 | 4 |
| , MD | Internal Medicine | Chicago, IL | $2,147 | 3 |
| , M.D | Internal Medicine | Ann Arbor, MI | $2,129 | 3 |
| , MD00022875 | Hematology & Oncology | Yakima, WA | $2,087 | 2 |
Ad
Manufacturing Companies
- Celgene Corporation $28.4M
Product Information
- Type Drug
- Total Payments $28.4M
- Total Doctors 118
- Transactions 509
About JCAR017
JCAR017 is a drug associated with $28.4M in payments to 118 healthcare providers, recorded across 509 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $21.1M was paid across 402 transactions to 106 doctors.
The most common payment nature for JCAR017 is "Unspecified" ($27.8M, 98.2% of total).
JCAR017 is associated with 20 research studies, including "A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM) (JCAR017-BCM-003)" ($8.2M).